Ignite Creation Date:
2025-12-24 @ 3:03 PM
Ignite Modification Date:
2026-03-13 @ 9:26 AM
Study NCT ID:
NCT00811759
Status:
UNKNOWN
Last Update Posted:
2010-10-07
First Post:
2008-12-18
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Sorafenib and Temozolomide in Treating Patients With Stage III or Stage IV Melanoma
Sponsor:
Gustave Roussy, Cancer Campus, Grand Paris
Organization:
Organization Data
Organization:
Class:
NIH
Study ID:
CDR0000626803
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
None
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None